Jasper Therapeutics, Inc. Common Stock (JSPR) is a publicly traded Healthcare sector company. As of May 21, 2026, JSPR trades at $0.89 with a market cap of $22.58M and a P/E ratio of -0.22. JSPR moved +0.00% today. Year to date, JSPR is -52.33%; over the trailing twelve months it is -82.69%. Its 52-week range spans $0.62 to $26.05. Analyst consensus is buy with an average price target of $7.88. Rallies surfaces JSPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Jasper Therapeutics Refiles Phase 2b Protocol with $14.1M Cash, $1.2M Loss: Jasper Therapeutics refiled its Phase 2b CSU protocol with FDA and selected two dosing regimens after January data showing 67% complete response (n=6) and 75% response (n=36) in extension studies with a mean 31-point UAS7 reduction. Cash totaled $14.1 million at March 31 and net loss was $1.2 million ($0.04/share).
| Metric | Value |
|---|---|
| Price | $0.89 |
| Market Cap | $22.58M |
| P/E Ratio | -0.22 |
| EPS | $-3.95 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.05 |
| 52-Week Low | $0.62 |
| Volume | 328 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-75.80M |
| Gross Margin | 0.00% |
6 analysts cover JSPR: 0 strong buy, 2 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.88.